A phase II trial of carboplatin and TS-1 for advanced or recurrent squamous cell lung cancer with the index of Ccr score

A phase II trial of carboplatin and TS-1 for advanced or recurrent squamous cell lung cancer with the index of Ccr score - OULCSG-1102

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005875

Enrollment

Registered

2011-06-30

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous cell lung cancer

Interventions

CBDCA + TS-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically confirned squamous cell lung cancer 2)Stage IIIB without any indications for radiotherapy or Stage IV 3)Measurable disease 4)No prior treatment 5)More than 20 years old 6)ECOG performance status of 0 or 1 7)Possible oral intake 8)Adequate organ functions 9)Estimated life expectancy of at least 12 weeks 10)Signed informed consent

Exclusion criteria

Exclusion criteria: 1)With adjuvant chemotherapy 2)The patients who have interstitial change 3)Allergy of the medication 4)Double cancer 5)Un-controlled pleural effusion and ascites 6)Severe complications, including AMI, un-controlled angina pectoris, and un-controlled diabetes and hypertension 7)Symptomatic brain metastasis 8)Radiation therapy which has thoracic field 9)The patients who treat with flucytosine 10)Pregnancy,breast feeding or wish of future bearing 11)Other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Progression free survival (PFS) PFS during maintenance therapy Overall survival Safety	—

Countries

Japan

Contacts

Public ContactTakashi Kijima

Osaka University Graduate School of Medicine Department of Respiratory Medicine, Allergy and Rheumatic Diseases

tkijima@imed3.med.osaka-u.ac.jp06-6879-3833

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026